The global Mice Model Market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029.

In the realm of biomedical research, mice models play a pivotal role in understanding human diseases and developing potential therapies. Key technologies driving advancements in this field include microinjection and CRISPR/Cas9, each offering distinct advantages for genetic manipulation and disease modeling.

Top Players:
Key players in the global mice model market include Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).

Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308

Microinjection Technology:
Microinjection involves the direct introduction of genetic material into the pronucleus of a fertilized egg. This technique enables precise control over genetic modifications, such as the introduction of transgenes or gene knockouts. Researchers use microinjection to create customized mice models that mimic human diseases, aiding in the study of disease mechanisms and therapeutic interventions.

CRISPR/Cas9 Technology:
CRISPR/Cas9 has revolutionized genetic engineering by allowing targeted modifications of specific genes within the mouse genome. This technology utilizes guide RNA to direct the Cas9 enzyme to specific DNA sequences, where it induces double-strand breaks. Researchers can then introduce desired genetic alterations, such as gene insertions, deletions, or substitutions. CRISPR/Cas9 offers unparalleled efficiency and precision, accelerating the generation of genetically modified mice models.

Current Trends and Developments:
1. Rising Demand for Disease-Specific Models: There is a growing emphasis on developing mice models that accurately replicate human diseases, facilitating the discovery of novel therapeutic targets and drug testing.
2. Technological Advancements: Continuous improvements in microinjection and CRISPR/Cas9 technologies enhance their efficiency, reducing costs and timelines associated with mice model generation.
3. Application in Precision Medicine: Mice models created through microinjection and CRISPR/Cas9 are instrumental in advancing precision medicine initiatives, enabling personalized treatment strategies based on genetic profiles.
4. Ethical Considerations and Alternatives: Efforts are ongoing to refine animal research practices, including the promotion of alternative models and ethical considerations in animal welfare.

Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=1308

In conclusion, the convergence of microinjection and CRISPR/Cas9 technologies in the mice model market signifies a transformative era in biomedical research. These advancements not only deepen our understanding of human biology and disease but also pave the way for innovative therapeutic approaches.